Botanix's Six-Month Sales of Topical Gel Miss Expectations, Euroz Says

MT Newswires Live

Jul 10, 2025

Botanix Pharmaceuticals (ASX:BOT) gross sales of about AU$25 million from January through June for its Sofdra topical gel for excessive underarm sweating, missed expectations, and is a "very disappointing" outcome, according to a Thursday report by Euroz Hartleys.

Net revenue came in at AU$5 million, well below Euroz's AU$14.8 million estimate and AU$8.8 million market consensus, due to weaker script volumes and net pricing.

Despite the miss, key launch metrics were encouraging, with strong refill rates, rising prescriber numbers, and high adherence, Euroz said.

The company's 70% share price drop appears overdone, with the market pricing in minimal Sofdra success, Euroz added.

Euroz maintained Botanix's buy rating but lowered its price target to AU$0.40 from AU$0.80.

Shares of the company fell 4% on market close.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550369711"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550369711\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550369711?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 13:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550369711","market":"fut","top_or_hot":-1,"title":"Botanix's Six-Month Sales of Topical Gel Miss Expectations, Euroz Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a> (ASX:BOT) gross sales of about AU$25 million from January through June for its Sofdra topical gel for excessive underarm sweating, missed expectations, and is a \"very disappointing\" outcome, according to a Thursday report by <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>Net revenue came in at AU$5 million, well below Euroz's AU$14.8 million estimate and AU$8.8 million market consensus, due to weaker script volumes and net pricing.</p><p>Despite the miss, key launch metrics were encouraging, with strong refill rates, rising prescriber numbers, and high adherence, Euroz said.</p><p>The company's 70% share price drop appears overdone, with the market pricing in minimal Sofdra success, Euroz added.</p><p>Euroz maintained Botanix's buy rating but lowered its price target to AU$0.40 from AU$0.80.</p><p>Shares of the company fell 4% on market close.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Botanix's Six-Month Sales of Topical Gel Miss Expectations, Euroz Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBotanix's Six-Month Sales of Topical Gel Miss Expectations, Euroz Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-10 13:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a> (ASX:BOT) gross sales of about AU$25 million from January through June for its Sofdra topical gel for excessive underarm sweating, missed expectations, and is a \"very disappointing\" outcome, according to a Thursday report by <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>Net revenue came in at AU$5 million, well below Euroz's AU$14.8 million estimate and AU$8.8 million market consensus, due to weaker script volumes and net pricing.</p><p>Despite the miss, key launch metrics were encouraging, with strong refill rates, rising prescriber numbers, and high adherence, Euroz said.</p><p>The company's 70% share price drop appears overdone, with the market pricing in minimal Sofdra success, Euroz added.</p><p>Euroz maintained Botanix's buy rating but lowered its price target to AU$0.40 from AU$0.80.</p><p>Shares of the company fell 4% on market close.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BOT.AU","symbol_name":"BOTANIX PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2550369711","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550369711","pubTimestamp":1752127061,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Botanix Pharmaceuticals  gross sales of about AU$25 million from January through June for its Sofdra topical gel for excessive underarm sweating, missed expectations, and is a \"very disappointing\" outcome, according to a Thursday report by Euroz Hartleys.Net revenue came in at AU$5 million, well below Euroz's AU$14.8 million estimate and AU$8.8 million market consensus, due to weaker script volumes and net pricing.Despite the miss, key launch metrics were encouraging, with strong refill rates, rising prescriber numbers, and high adherence, Euroz said.The company's 70% share price drop appears overdone, with the market pricing in minimal Sofdra success, Euroz added.Euroz maintained Botanix's buy rating but lowered its price target to AU$0.40 from AU$0.80.Shares of the company fell 4% on market close.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BOT.AU":"BOTANIX PHARMACEUTICALS LTD"},"translate_title":"Euroz表示，Botanix外用凝胶六个月销量未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOT.AU":0.9},"content_text":"Botanix Pharmaceuticals (ASX:BOT) gross sales of about AU$25 million from January through June for its Sofdra topical gel for excessive underarm sweating, missed expectations, and is a \"very disappointing\" outcome, according to a Thursday report by Euroz Hartleys.Net revenue came in at AU$5 million, well below Euroz's AU$14.8 million estimate and AU$8.8 million market consensus, due to weaker script volumes and net pricing.Despite the miss, key launch metrics were encouraging, with strong refill rates, rising prescriber numbers, and high adherence, Euroz said.The company's 70% share price drop appears overdone, with the market pricing in minimal Sofdra success, Euroz added.Euroz maintained Botanix's buy rating but lowered its price target to AU$0.40 from AU$0.80.Shares of the company fell 4% on market close.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}